Abstract
A s mentioned in a previous feature article,* disease management (DM) may become the dominant strategy for healthcare delivery in the US. And a number of other countries are exploring DM strategies, including the UK. While ongoing structural reforms in the UK National Health Service (NHS) provide new opportunities for DM, a recent report suggests there are several hurdles to overcome before the approach is widely adopted - not least a pervasive culture of suspicion within the NHS towards the pharmaceutical industry.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
